Nicole Germino
Stock Analyst at Truist Securities
(2.19)
# 2,693
Out of 4,735 analysts
18
Total ratings
40%
Success rate
1.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Buy | $100 → $105 | $76.75 | +36.81% | 7 | Nov 1, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $21 | $3.52 | +496.59% | 1 | Sep 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $21 | $6.19 | +239.26% | 1 | Jun 28, 2024 | |
| SGMO Sangamo Therapeutics | Downgrades: Hold | n/a | $1.13 | - | 4 | Nov 7, 2023 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $14.30 | +67.83% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $14.70 | - | 2 | Sep 3, 2021 |
Insmed
Nov 1, 2024
Reiterates: Buy
Price Target: $100 → $105
Current: $76.75
Upside: +36.81%
Perspective Therapeutics
Sep 25, 2024
Initiates: Buy
Price Target: $21
Current: $3.52
Upside: +496.59%
Y-mAbs Therapeutics
Jun 28, 2024
Initiates: Buy
Price Target: $21
Current: $6.19
Upside: +239.26%
Sangamo Therapeutics
Nov 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.13
Upside: -
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $14.30
Upside: +67.83%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $14.70
Upside: -